The main purpose of the study is to assess the safety and tolerability of AZD9829 in different dose levels for patients with hematological malignancies.

AZD9829 is considered investigtional, which means it is not approved by the U.S. Food and Drug Administration (FDA). 

This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with CDK4/6i and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer.

The purpose of this research study is to better understand the causes of fatty liver recurrence and the development of metabolic illnesses such as diabetes, high blood pressure, weight gain, and abnormal cholesterol levels in patients who have undergone liver transplantation.

This clinical trial is for men and women with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML).

The purpose of this study is to determine whether the study drug, Rusfertide, is safe and effective for treating Polycythemia Vera for those that require routine phlebotomies (removal of red blood cells) to control their disease.

Participants in this study should have previously participated in a study in which Rusfertide (also known as PTG-300) was being studied. Participants will continue to receive Rusfertide in this study.

The purpose of this study is to see if ABBV-787 (the study drug) is safe and to determine if ABBV-787 has an effect on relapsed or refractory (R/R) Acute Myeloid Leukemia (AML). This study is for patients with Acute Myeloid Leukemia (AML) that have relapsed or are refractory (R/R; meaning they have returned, grown, or progressed during or after one or more prior treatments).

ABBV-787 is considered investigational which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

The purpose of the study is to collect more information on the safety of BNT116 in combination with cemiplimab and to see how well combining the study drugs work in treating advanced non-small cell lung cancer (NSCLC).
   
The study is researching an investigational drug, called BNT116, in combination with cemiplimab. Investigational means that it has not yet been approved by the U.S. Food and Drug Administration (FDA) alone or in combination with other drugs.
   

In this clinical trial, we hope to learn the effectiveness of cemiplimab with chemotherapy or cemiplimab with stereotactic body radiation therapy (SBRT) as treatment for clinical stage IB-III (N2) non-small cell lung cancer prior to surgery and cemiplimab for one year following surgery. 

Cemiplimab is approved by the U.S. Food and Drug Administration (FDA) for advanced disease, however, it is considered investigational in this study because it is not approved for early-stage disease.

The purpose of this research study is to determine if Seladelpar is effective at normalizing disease markers in subjects with primary biliary cholangitis (PBC) who are currently on ursodeoxycholic acid (UDCA) treatment or intolerant to UDCA. 

The purpose of this study is to learn how whole-body hyperthermia (achieved in a sauna) may work to decrease feelings of depression and anxiety. We know that this intervention works in adults with depression, but we do not know how it works. We also want to find out if postpartum women will find this intervention acceptable, and whether the way it works may be different in postpartum women from other people.